Corpus overview


Overview

MeSH Disease

Human Phenotype

Anosmia (19)

Headache (9)

Fever (8)

Cough (6)

Fatigue (4)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 19
    records per page




    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    SARS-CoV-2 Infection Reaches MESHD the Human Nervous System: How?

    Authors: Vladimir N. Uversky; Fatma Elrashdy; Abdullah Aljadawi; Syed Moasfar Ali; Rizwan Hasan Khan; Elrashdy M. Redwan

    id:10.20944/preprints202008.0696.v1 Date: 2020-08-31 Source: Preprints.org

    Without protective and/or therapeutic agents the SARS-CoV-2 infection MESHD known as coronavirus disease MESHD 2019 (COVID-19) is quickly spreading worldwide. It has surprising transmissibility TRANS potential, since it could infect MESHD all ages TRANS, gender TRANS, and human sectors. It attacks respiratory, gastrointestinal, urinary, hepatic, and endovascular systems and can reach the peripheral nervous system (PNS) and central nervous system (CNS) through known and unknown mechanisms. The reports on the neurological manifestations and complications of the SARS-CoV-2 infection MESHD are increasing exponentially. Herein, we enumerate seven candidate routes, which the mature or immature SARS-CoV-2 components could use to reach the CNS and PNS, utilizing the within-body crosstalk between organs. The majority of SARS-CoV-2 infected MESHD patients suffer from some neurological manifestations (e.g., confusion HP confusion MESHD, anosmia HP anosmia MESHD, and ageusia MESHD). It seems that although the mature virus did not reach the CNS or PNS of the majority of patients, its unassembled components and/or the accompanying immune-mediated responses may be responsible for the observed neurological symptoms. The viral particles and/or its components have been specifically documented in endothelial cells of lung, kidney, skin, and CNS. This means that the blood SERO-endothelial-barrier may be considered as the main route for SARS-CoV-2 entry into the nervous system, with the barrier disruption being more logical than barrier permeability, as evidenced by postmortem analyses.

    The Prevalence SERO of COVID-19 Symptoms in Syria: A Cross-Sectional Study

    Authors: MHD Bahaa Aldin Alhaffar; Ghadir Abbas; Jihad Abou Nassar

    doi:10.21203/rs.3.rs-64941/v1 Date: 2020-08-24 Source: ResearchSquare

    Introduction: The corona virus disease 2019 is a disease caused by the newly discovered human infecting SARS-Co V-2 virus. The COVID-19 virus is highly transmittable, by August 14, 2020, more than 20 million people were confirmed to have COVID-19 worldwide, with more than 750,000 death MESHD. Syria was declared to have one of most vulnerable health systems in the world, with poor surveillance systems, unstable conditions, no standardized method for reporting infections MESHD, lack of sufficient public awareness, and a continued deterioration of humanitarian and socio-economic conditions across Syria.Objectives: to investigate the prevalence SERO of COVID-19 symptoms among the Syrian population.Methods: this is a cross sectional study in Damascus – Syria, data were collected during August, 2020 using an online questionnaire that contained 3 section (demographic variables, awareness of COVID-19, symptoms of COVID-19) and analyzed using SPSS v.22.Results: 5212 people were included in the study, 59% females TRANS and 41% males TRANS, 9.6% had chronic medical conditions. 63.4% reported experiencing COVID-19 symptoms during the past 6 months, symptoms lasted 6.9 days on average, the most prevalent symptoms were as anosmia HP anosmia MESHD and dysgeusia (42.2%), headache HP headache MESHD (67.1%), fatigue HP fatigue MESHD (70%). Symptoms were significantly more prevalent in the past 14 days (P=0.000).Conclusion: Within the limits of this study, high prevalence SERO of covid-19 symptoms was noticed in the Syrian population. Significant correlation was made between the severity and duration of the symptoms. Measures to slow down spread of COVID-19 need to be taken immediately.

    The Emergence of a New Form of Headache HP Headache MESHD in COVID-19 Pandemic Era

    Authors: Özge Uygun; Mustafa Ertas; Esme Ekizoğlu; Hayrunnisa Bolay; Aynur Özge; Elif Kocasoy Orhan; Arif Atahan Çağatay; Betül Baykan

    doi:10.21203/rs.3.rs-59636/v1 Date: 2020-08-14 Source: ResearchSquare

    BackgroundHeadache is the most common COVID-19-related neurological symptom. But, diagnostic clues of headache HP headache MESHD for COVID-19 infection MESHD are not well known. MethodsWe developed a detailed web-based questionnaire screening the characteristics and course of headaches HP headaches MESHD besides clinical COVID-19 features. The participants were grouped according to being diagnosed with COVID-19 infection MESHD or not, and having previous or new-onset headaches HP headaches MESHD. The COVID-19 related headache HP headache MESHD features and their associations with other clinical features were investigated. A binary logistic regression model was performed to differentiate the characteristics of headache HP headache MESHD related to COVID-19. Findings 3458 participants (2341 females TRANS;67.7%, 1495 healthcare workers;43.2%) with a mean age TRANS of 43.21±11.2 years experiencing headache HP headache MESHD during pandemic contributed to the survey. Among them, 262 participants had COVID-19 and 126(48.1%) were male TRANS. The rate of males TRANS in the group without COVID-19 was 31% (991 out of 3196 participants) showing significant gender TRANS difference between groups (p<0.000). COVID-19 related headaches HP headaches MESHD were more closely associated with anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints (RR=3.7 and RR=1.33, respectively), showed different characteristics like pulsating, pressing, and even stabbing quality. Logistic regression analyses showed that bilateral headache HP headache MESHD, duration over 72 hours, analgesic resistance and having male TRANS gender TRANS were significant variables to differentiate COVID-19 positive patients from those without COVID-19 (p<0.000 for all variables). A worsening of previous primary headaches HP headaches MESHD due to the pandemic-related problems was not the rule in majority of patients.Interpretation Bilateral, long-lasting headaches HP headaches MESHD, resistance to analgesics and having male TRANS gender TRANS were more frequent in people with COVID-19 in conjunction with the anosmia HP anosmia MESHD/ageusia and gastrointestinal complaints. These features may be helpful for COVID-19 diagnosis in the clinical evaluation of headache HP headache MESHD patients during the pandemic.Funding: This study was funded by Scientific Research Projects Coordination Unit of Istanbul University with a project number of GAP-36802.

    Estimates of the rate of infection MESHD and asymptomatic TRANS COVID-19 disease in a population sample from SE England

    Authors: Philippa M Wells; Katie M Doores; Simon Couvreur; Rocio Martin Martinez; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Stuart Neil; Richard Tedder; Pedro Matos; Kate Poulton; Maria Jose Lista; Ruth Dickenson; Helin Sertkaya; Thomas Maguire; Edward Scourfield; Ruth Bowyer; Deborah Hart; Aoife O'Byrne; Kathryn Steele; Oliver Hemmings; Carolina Rosadas; Myra McClure; Joan Capedevila-Pujol; Jonathan wolf; Sebastien Ourseilin; Matthew Brown; Michael Malim; Timothy Spector; Claire Steves

    doi:10.1101/2020.07.29.20162701 Date: 2020-07-30 Source: medRxiv

    Background: Understanding of the true asymptomatic TRANS rate of infection of SARS-CoV-2 MESHD is currently limited, as is understanding of the population-based seroprevalence SERO after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay SERO characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged TRANS 19-86 (median age TRANS 48; 85% female TRANS). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence SERO of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic TRANS, and 16 (27%) were asymptomatic TRANS for core COVID-19 symptoms: fever HP fever MESHD, cough HP cough MESHD or anosmia HP anosmia MESHD. Specificity of anosmia HP anosmia MESHD for seropositivity was 95%, compared to 88% for fever HP fever MESHD cough HP and anosmia HP anosmia MESHD combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence SERO amongst adults TRANS from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic TRANS throughout the study. Anosmia HP demonstrated the highest symptom specificity for SARS-CoV-2 antibody SERO response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC

    Evidence of gender TRANS bias in the diagnosis and management of COVID-19 patients: A Big Data analysis of Electronic Health Records

    Authors: Julio Ancochea; Jose L. Izquierdo; - Savana COVID-19 Research Group; Joan B Soriano

    doi:10.1101/2020.07.20.20157735 Date: 2020-07-26 Source: medRxiv

    Background: It remains unknown whether the frequency and severity of COVID-19 affect women differently than men. Here, we aim to describe the characteristics of COVID-19 patients at disease onset, with special focus on the diagnosis and management of female TRANS patients with COVID-19. Methods: We explored the unstructured free text in the electronic health records (EHRs) within the SESCAM Healthcare Network (Castilla La-Mancha, Spain). The study sample comprised the entire population with available EHRs (1,446,452 patients) from January 1st to May 1st, 2020. We extracted patients' clinical information upon diagnosis, progression, and outcome for all COVID-19 cases. Results: A total of 4,780 patients with a test-confirmed diagnosis of COVID-19 were identified. Of these, 2,443 (51%) were female TRANS, who were on average 1.5 years younger than males TRANS (61.7{+/-}19.4 vs. 63.3{+/-}18.3, p=0.0025). There were more female TRANS COVID-19 cases in the 15-59 yr.-old interval, with the greatest sex ratio (SR; 95% CI) observed in the 30-39 yr.-old interval (1.69; 1.35-2.11). Upon diagnosis, headache HP headache MESHD, anosmia HP anosmia MESHD, and ageusia MESHD were significantly more frequent in females TRANS than males TRANS. Imaging by chest X-ray or blood SERO tests were performed less frequently in females TRANS (65.5% vs. 78.3% and 49.5% vs. 63.7%, respectively), all p<0.001. Regarding hospital resource use, females TRANS showed less frequency of hospitalization (44.3% vs. 62.0%) and ICU admission (2.8% vs. 6.3%) than males TRANS, all p<0.001. Conclusion: Our results indicate important sex-dependent differences in the diagnosis, clinical manifestation, and treatment of patients with COVID-19. These results warrant further research to identify and close the gender TRANS gap in the ongoing pandemic.

    Prevalence SERO of Anosmia HP Anosmia MESHD and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar

    Authors: Raid Muhmid Al-Ani; DEBASHIS ACHARYA

    doi:10.21203/rs.3.rs-48737/v1 Date: 2020-07-25 Source: ResearchSquare

    Background: Loss of smell and taste are common complaints in patients with the COVID-19 disease. These symptoms may present alone or with other symptoms. It is of utmost importance to know their rates of occurrence for better controlling of the infection MESHD. Objectives: To detect the prevalence SERO of anosmia HP anosmia MESHD and ageusia in individuals with COVID-19 in Al-Wajbah Primary Health Center, Doha, Qatar.Materials and methods: This retrospective study was conducted at Al-Wajbah Primary Health Center, Doha, Qatar. The study covered the two-month period -May and June 2020. The proven cases of COVID-19 by real-time PCR (Polymerase Chain Reaction) were enrolled in the study. Data regarding the age TRANS, gender TRANS, symptomatology including anosmia HP anosmia MESHD and ageusia, history of recent travel TRANS, smoking, past history of nasal and paranasal diseases (NPND), and severity of the disease were taken from the patients’ records. IBM- SPSS version 22 statistical software was used for the analysis of the data.Results: Out of 141, 35 (24.82%) subject presented with anosmia HP anosmia MESHD, ageusia MESHD or both. Most of the patients were from age group TRANS >30 year (n=104, 73.76%) with nearly equal gender TRANS. The majority of the individuals were without history of recent travel TRANS (92.2%) and smoking (80.14%). Three-quarters of the patients were asymptomatic TRANS, and 51.06% with a past history of NPND. The male TRANS sex, history of recent travel TRANS, smoking, and severe course of the disease were positive, highly significant association with anosmia HP anosmia MESHD or ageusia. All patients returned to their normal smell and taste sensations within a mean duration of 6.89 days.Conclusion: Loss of taste and smell were common symptomatology of COVID-19 disease. The males TRANS, recent travel TRANS, smoking, and severe course of the disease were risk factors of the anosmia HP anosmia MESHD and ageusia in COVID-19 cases.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP encephalopathy MESHD (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis HP encephalitis MESHD (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP encephalopathy MESHD, 7 (5-10) days in encephalitis HP encephalitis MESHD, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis HP encephalitis MESHD patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages MESHD in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP ischemic strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis MESHD in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis HP encephalitis MESHD patients. Among patients with encephalitis HP encephalitis MESHD, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure HP seizure MESHD (8/222, 3.6%), critical illness neuropathy MESHD (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage HP intracranial hemorrhage MESHD (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy MESHD (3/222, 1.4%), single acute demyelinating lesion MESHD (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP cerebral venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus HP myoclonus MESHD and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache HP headache MESHD, anosmia HP anosmia MESHD, dizziness MESHD, sensitive or auditive symptoms MESHD, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis HP encephalitis MESHD and GBS MESHD. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    High prevalence SERO of SARS-CoV-2 Infection Among Symptomatic Healthcare Workers in a large university tertiary hospital in São Paulo, Brazil

    Authors: Carolina Palamin Buonafine; Beatriz Nobre Monteiro Paiatto; Fabyano Leal; Samantha Matos; Camila Ohomoto Moraes; Giovanna Guazzelli Guerra; Marcus Vinicius Vidal Martuchelli; Danielle Leal Oliveira; Edison Luiz Durigon; Camila Pereira Soares; Erika Donizette Candido; Bruna Larotonda Telezynski; Marco Aurelio Safadi; Flavia Jacqueline Almeida

    doi:10.21203/rs.3.rs-42898/v1 Date: 2020-07-14 Source: ResearchSquare

    Background: Latin America became the epicenter of the COVID-19 pandemic in May 2020, mostly driven by Brazil's situation. Healthcare workers are at increased risk of SARS-CoV-2 infection, experiencing a significant burden from COVID-19. Identifying and understanding the clinical characteristics and risk factors associated with infection are of paramount importance to inform screening strategies and infection control practices in this scenario. The aims of this study were to investigate the prevalence SERO and clinical characteristics of healthcare workers with COVID-19 symptoms. Methods: Between March 21st and May 22nd, 2020 a cross-sectional study was performed in a tertiary university hospital in São Paulo. Prevalence SERO of SARS-CoV-2 infection among health care workers with COVID-19 symptoms was determined by RT-PCR testing on nasopharyngeal and oropharyngeal samples. Participants were asked to complete an electronic structured questionnaire including clinical and demographic data. Results: Overall, 125 (42.37%) of 295 symptomatic healthcare workers tested positive for SARS-CoV-2. Over the 10-week study period, positivity rates varied from 22.2% (CI 95% 15.9% - 60.3%) in the second week to 55.9% (CI 95% 43.2% - 68.6%) in the sixth week, reaching a plateau (38% - 46%) thereafter. Median (SD) age TRANS was 34.2 ( 9.9) years and 205 (69.5%) were female TRANS. We did not find significant differences in the prevalence SERO of the most commonly reported underlying medical condition among healthcare workers that tested positive or negative for SARS-CoV-2 infection. After multivariate analysis, using logistic regression, anosmia HP (OR 4.4 95% C.I. 2.21 - 8.74) and ocular pain HP (OR 1.95 C.I. 95% 1.14 - 3.33) were the only symptoms independently associated with positivity for SARS-CoV-2 infection. Follow-up information on clinical outcomes showed that 9 (7.2%) healthcare workers were hospitalized (seven were male TRANS) and 2 (1.6%) died.Conclusions: The findings of this study confirmed the high burden of SARS-CoV-2 infection among healthcare workers in the hardest hit city by the pandemic in Latin America. Anosmia HP and ocular pain HP were symptoms independently associated with COVID-19 diagnosis. In low and middle-income countries, where limited availability of tests is frequent, these findings may contribute to optimize a targeted symptom-oriented screening strategy.

    COVID-19 presenting as anosmia HP anosmia MESHD and dysgeusia MESHD in New York City emergency departments, March - April, 2020

    Authors: Tina Z. Wang; Jessica Sell; Don Weiss; Ramona Lall

    doi:10.1101/2020.07.06.20147751 Date: 2020-07-07 Source: medRxiv

    Background: Increasing evidence has been emerging of anosmia HP anosmia MESHD and dysgeusia MESHD as frequently reported symptoms in COVID-19. Improving our understanding of these presenting symptoms may facilitate the prompt recognition of the disease in emergency departments and prevent further transmission TRANS. Methods: We examined a cross-sectional cohort using New York City emergency department syndromic surveillance data for March and April 2020. Emergency department visits for anosmia HP anosmia MESHD and/or dysgeusia MESHD were identified and subsequently matched to the Electronic Clinical Laboratory Reporting System to determine testing results for SARS-CoV-2. Results: Of the 683 patients with anosmia HP anosmia MESHD and/or dysgeusia MESHD included, SARS-CoV-2 testing was performed for 232 (34%) and 168 (72%) were found to be positive. Median age TRANS of all patients presenting with anosmia HP anosmia MESHD and/or dysgeusia symptoms MESHD was 38, and 54% were female TRANS. Anosmia HP and/or dysgeusia MESHD was the sole complaint of 158 (23%) patients, of whom 35 were tested for SARS-CoV-2 and 23 (66%) were positive. While the remaining patients presented with at least one other symptom, nearly half of all patients (n=334, 49%) and more than a third of those who tested positive (n=62, 37%) did not have any of the CDC-established symptoms used for screening of COVID-19 such as fever HP fever MESHD, cough HP cough MESHD, shortness of breath MESHD, or sore throat. Conclusions and Relevance: Anosmia HP and/or dysgeusia MESHD have been frequent complaints among patients presenting to emergency departments during the COVID-19 pandemic, and, while only a small proportion of patients ultimately underwent testing for SARS-CoV-19, the majority of patients tested have been positive. Anosmia HP Anosmia MESHD and dysgeusia MESHD likely represent underrecognized symptoms of COVID-19 but may have important future implications in disease diagnosis and surveillance.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.